Answers are grounded in this paper and cite their sources.
Metastasis is the major cause of mortality from malignant tumors. Metastatic cancer cells spread to various organs via the vascular system (hematogenic metastasis) and/or the lymphatic system (lymphogenic metastasis). Compared with our understanding of a tumor's vascular system, our understanding of its lymphatic system is minimal, although it has been known for some time that lymphatic vessels are present in the margins of animal and human tumors. Indeed, invasion of peritumor lymphatics is considered to be a poor prognostic factor for patients with some tumors (e.g., breast, colorectal, and endometrial cancers), and lymphatic metastasis is a major cause of morbidity and mortality for others (e.g., melanoma, head and neck, lung, and cervical cancers; www.uptodate.com). For nearly a century, it has been a hotly debated issue whether anatomically defined lymphatic vessels are present within solid tumors (1) and, if so, whether they function (2) (Fig. 1). However, the discovery of two lymphangiogenic molecules, vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR3 changed the landscape for lymphatic studies by providing the critical molecular players and tools (3). A series of recent reports (4–8) suggests that overexpression of VEGF-C or -D is associated with lymphangiogenesis in tumors and with increased lymphatic metastasis in mice. Despite the aforementioned studies (4–8), many questions remain regarding the molecular mechanisms of lymphangiogenesis, the specificity of growth factors and lymphatic markers, and the ability of lymphatics to function within tumors.
No takes yet. Share an insight, caveat, or question.
R. K. Jain (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: